Currently, there are 190.70M common shares owned by the public and among those 188.24M shares have been available to trade.
The company’s stock has a 5-day price change of -24.98% and -17.87% over the past three months. CHX shares are trading -17.18% year to date (YTD), with the 12-month market performance down to -42.76% lower. It has a 12-month low price of $22.32 and touched a high of $39.95 over the same period. CHX has an average intraday trading volume of 4.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -21.34%, -22.24%, and -25.33% respectively.
Institutional ownership of ChampionX Corp (NASDAQ: CHX) shares accounts for 91.63% of the company’s 190.70M shares outstanding.
It has a market capitalization of $4.30B and a beta (3y monthly) value of 1.56. The stock’s trailing 12-month PE ratio is 13.61, while the earnings-per-share (ttm) stands at $1.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.73% over the week and 3.75% over the month.
Analysts forecast that ChampionX Corp (CHX) will achieve an EPS of 0.45 for the current quarter, 0.44 for the next quarter and 2.26 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.43 while analysts give the company a high EPS estimate of 0.43. Comparatively, EPS for the current quarter was 0.5 a year ago. Earnings per share for the fiscal year are expected to decrease by -4.07%, and 9.60% over the next financial year.
Looking at the support for the CHX, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on January 08, 2024, with the firm’s price target at $38-$32. Barclays coverage for the ChampionX Corp (CHX) stock in a research note released on October 17, 2023 offered a Overweight rating with a price target of $42. CapitalOne was of a view on July 14, 2023 that the stock is Overweight, while Barclays gave the stock Equal Weight rating on October 06, 2022, issuing a price target of $38- $28. The Benchmark Company on their part issued Buy rating on August 25, 2022.
